A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data

PADOVA has successfully recruited an early-stage PD population to test the effect of prasinezumab when added to background SOC.

Authors

Loes C.A. Rutten‐Jacobs (ORCID: https://orcid.org/0000-0003-3223-885X)
Kirsten I. Taylor (ORCID: https://orcid.org/0000-0002-2480-3137)
Dylan Trundell (ORCID: https://orcid.org/0000-0003-3542-8181)
Nicola Pavese (ORCID: https://orcid.org/0000-0002-6801-6194)
Annabelle Monnet
Fabrizio Stocchi (ORCID: https://orcid.org/0000-0002-5763-0033)
Ronald B. Postuma (ORCID: https://orcid.org/0000-0002-6468-4734)
Gesine Respondek (ORCID: https://orcid.org/0000-0002-6851-6164)
Paulo Fontoura (ORCID: https://orcid.org/0000-0002-3883-257X)
Hanno Svoboda (ORCID: https://orcid.org/0009-0005-1910-586X)
Gennaro Pagano (ORCID: https://orcid.org/0000-0002-6247-8988)
Nathalie Pross
Thomas Kustermann (ORCID: https://orcid.org/0000-0003-3263-4174)
Rachelle S. Doody
Tanya Simuni (ORCID: https://orcid.org/0000-0002-2347-1644)
Benedicte Ricci
Tania Nikolcheva (ORCID: https://orcid.org/0009-0004-7610-4700)
Klaus Seppi (ORCID: https://orcid.org/0000-0001-6503-1455)
Azad Bonni (ORCID: https://orcid.org/0000-0003-1391-1500)
Kenneth Marek (ORCID: https://orcid.org/0000-0002-4197-5627)
Nima Shariati

Institutions

Northwestern University (US)
Roche (Switzerland) (CH)
Montreal Neurological Institute and Hospital (CA)
Innsbruck Medical University (AT)
Vita-Salute San Raffaele University (IT)
Institute for Neurodegenerative Disorders (US)
Roche (United Kingdom) (GB)
Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Newcastle University (GB)

Publication Details

Journal: Parkinsonism & Related Disorders
Published: 2024-12-29
DOI: https://doi.org/10.1016/j.parkreldis.2024.107257
Citations: 7
Primary Topic: Parkinson's Disease Mechanisms and Treatments
Type: article
Field-Weighted Citation Impact: 2.58

Funders

F. Hoffmann-La Roche

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data

Loes C.A. Rutten‐Jacobs, Kirsten I. Taylor, Dylan Trundell, Nicola Pavese, Annabelle Monnet, Fabrizio Stocchi, Ronald B. Postuma, Gesine Respondek, Paulo Fontoura, Hanno Svoboda, Gennaro Pagano, Nathalie Pross, Thomas Kustermann, Rachelle S. Doody, Tanya Simuni, Benedicte Ricci, Tania Nikolcheva, Klaus Seppi, Azad Bonni, Kenneth Marek, Nima Shariati

December 29, 2024article en

7 citations

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data

Authors

Institutions

Publication Details

Funders

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.